

**Fiscal Year 2013 Autism Research Program  
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding Available	Submission Deadline
<p><b>Idea Development Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">Application Instructions</a></li> </ul> <p>Grants.gov Funding Opportunity Number: <a href="#">W81XWH-13-ARP-IDA</a></p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports the development of innovative, high-impact ideas that advance the understanding of autism spectrum disorder (ASD) and lead to improved outcomes.</li> <li>• Applications in the following areas are encouraged: <ul style="list-style-type: none"> <li>○ Understanding factors underlying the heterogeneity of clinical expression, or response to treatment of ASD, excluding new gene discovery</li> <li>○ Conditions co-occurring with ASD</li> <li>○ Validation of new or existing therapeutic targets, excluding new gene discovery</li> <li>○ Psychosocial factors promoting success in key transitions to independence for individuals living with ASD</li> <li>○ Factors promoting success in family/caregiver well-being</li> </ul> </li> <li>• Preliminary data are <i>required</i>.</li> <li>• Behavioral clinical trials and correlative studies associated with clinical trials <i>may</i> be allowed if they are <i>no greater than minimal risk</i> as determined by the local Institutional Review Board and Human Research Protection Office</li> <li>• <b>Multiple Principal Investigator (PI) option:</b> Up to three investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.</li> <li>• Investigators are encouraged to submit their data to the National Database for Autism Research, a secure bioinformatics platform for data sharing.</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding for the entire period of performance is <b>\$350,000</b> for direct costs (plus indirect costs).</li> <li>• For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed <b>\$350,000</b> in direct costs.</li> <li>• Maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application:</b> July 2, 2013 5:00 p.m. Eastern time (ET) Pre-application is required; application submission is by invitation only.</p> <p><b>Invitation to Submit an Application:</b> August 2013</p> <p><b>Application:</b> October 15, 2013 11:59 p.m. ET</p>

**Fiscal Year 2013 Autism Research Program  
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding Available	Submission Deadline
<p><b>Pilot Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">Application Instructions</a></li> </ul> <p>Grants.gov Funding Opportunity Number: <a href="#">W81XWH-13-ARP-PA</a></p>	<p>Investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ASD forward.</li> <li>• Applications in the following areas are encouraged: <ul style="list-style-type: none"> <li>○ Understanding factors underlying the heterogeneity of clinical expression, or response to treatment of ASD, excluding new gene discovery</li> <li>○ Conditions co-occurring with ASD</li> <li>○ Validation of new or existing therapeutic targets, excluding new gene discovery</li> <li>○ Psychosocial factors promoting success in key transitions to independence for individuals living with ASD</li> <li>○ Factors promoting success in family/caregiver well-being</li> </ul> </li> <li>• Preliminary data are <i>not allowed</i>.</li> <li>• Clinical trials are <i>not allowed</i>.</li> <li>• Not intended to support the continuation of existing studies or the next logical extension and/or incremental step.</li> <li>• Projects involving human subjects or human biological substances must be either exempt under Title 32, Code of Federal Regulations, Part 219, Section 101(b) (32 CFR 219.101(b)) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding for the entire period of performance is <b>\$100,000</b> for direct costs (plus indirect costs)</li> <li>• Maximum period of performance is <b>2</b> years</li> </ul>	<p><b>Pre-Application:</b> July 2, 2013 5:00 p.m. ET</p> <p>Pre-application is required; application submission is by invitation only.</p> <p><b>Invitation to Submit an Application:</b> August 2013</p> <p><b>Application:</b> October 8, 2013 11:59 p.m. ET</p>